These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29065740)

  • 41. Family physicians' knowledge and screening of chronic hepatitis and liver cancer.
    Ferrante JM; Winston DG; Chen PH; de la Torre AN
    Fam Med; 2008 May; 40(5):345-51. PubMed ID: 18465284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model.
    Saab S; Ly D; Nieto J; Kanwal F; Lu D; Raman S; Amado R; Nuesse B; Durazo F; Han S; Farmer DG; Ghobrial RM; Yersiz H; Chen P; Schwegel K; Goldstein LI; Tong M; Busuttil RW
    Liver Transpl; 2003 Jul; 9(7):672-81. PubMed ID: 12827551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
    Jacobs RJ; Koff RS; Meyerhoff AS
    Am J Gastroenterol; 2002 Feb; 97(2):427-34. PubMed ID: 11866283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening.
    Sarpel D; Baichoo E; Dieterich DT
    Expert Rev Anti Infect Ther; 2016; 14(5):511-21. PubMed ID: 27043049
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The budget impact of cervical cancer screening using HPV primary screening.
    Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
    Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    Deuffic-Burban S; Obach D; Canva V; Pol S; Roudot-Thoraval F; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
    Stahmeyer JT; Krauth C; Bert F; Pfeiffer-Vornkahl H; Alshuth U; Hüppe D; Mauss S; Rossol S
    J Viral Hepat; 2016 Feb; 23(2):105-15. PubMed ID: 26411532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
    Elbasha EH; Chhatwal J; Ferrante SA; El Khoury AC; Laires PA
    Appl Health Econ Health Policy; 2013 Feb; 11(1):65-78. PubMed ID: 23355388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey.
    Bechini A; Falla A; Ahmad A; Veldhuijzen I; Boccalini S; Porchia B; Levi M
    BMC Infect Dis; 2015 Aug; 15():353. PubMed ID: 26286525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.
    García-Herola A; Domínguez-Hernández R; Casado MÁ
    PLoS One; 2021; 16(12):e0260608. PubMed ID: 34928962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver disease in Viet Nam: screening, surveillance, management and education: a 5-year plan and call to action.
    Gish RG; Bui TD; Nguyen CT; Nguyen DT; Tran HV; Tran DM; Trinh HN;
    J Gastroenterol Hepatol; 2012 Feb; 27(2):238-47. PubMed ID: 22098550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis.
    Martin EG; Paltiel AD; Walensky RP; Schackman BR
    Value Health; 2010 Dec; 13(8):893-902. PubMed ID: 20950323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cost-effectiveness of birth cohort screening for hepatitis C antibody in US primary care settings.
    Vuppalanchi R; Kwo PY
    Gastroenterology; 2013 Feb; 144(2):457-459. PubMed ID: 23260498
    [No Abstract]   [Full Text] [Related]  

  • 58. Diagnosis and treatment of chronic viral hepatitis B and C: doctrinary approach.
    Husic-Selimovic A; Vukobrat-Bijedic Z; Bevanda M; Mesihovic R; Zerem E; Ahmetagic S; Trbojevic S; Verhaz A; Kezic Z; Zildzic M; Bojanic J; Petrovic J; Stojic V; Ferhatovic M; Ibrahimpasic N; Mrdjen V; Zivlak N; Barac T; Bebek-Ivankovic H; Calkic L; Karin M; Dobrovoljski A; Rajic R; Skrbic M; Babic N; Bevanda-Glibo D;
    Med Arch; 2012; 66(3 Suppl 1):56-69. PubMed ID: 22937696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preliminary analysis of short-term financial implications of a prevention bonus program: first results from the German Statutory Health Insurance.
    Stock S; Stollenwerk B; Klever-Deichert G; Redaelli M; Büscher G; Graf C; Möhlendick K; Mai J; Gerber A; Lüngen M; Lauterbach KW
    Int J Public Health; 2008; 53(2):78-86. PubMed ID: 18681336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
    Aljutaili M; Becker C; Witt S; Holle R; Leidl R; Block M; Brachmann J; Silber S; Bestehorn K; Stollenwerk B
    BMC Health Serv Res; 2014 Jun; 14():263. PubMed ID: 24938674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.